NATCO Pharma has informed that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, the 12th day of November, 2024 to consider among other things, the following items of business and related matters: To consider the Unaudited Financial Results for the quarter and Half year ended 30th September, 2024 and to consider 2nd interim dividend, if any, for the financial Year ending 2024-25. Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time trading window for dealing in the securities of the Company by the Employee(s), connected persons and their immediate relatives will be closed from 29th October, 2024 to 14th November, 2024. Trading window will be re-opened on 15th November, 2024.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: